US 8,012,936 B2Granted

Tau fragments for immunotherapy

AssigneeNew York University

InventorsEinar Sigurdsson, Ayodeji Asuni

Life of this patent

Estimating the term…

Abstract

The present invention relates to methods of treating and preventing Alzheimer's Disease or other tauopathies in a subject by administering a tau protein, its immunogenic epitopes, or antibodies recognizing the tau protein or its immunogenic epitopes under conditions effective to treat or prevent Alzheimer's Disease of other tauopathies. Also disclosed are methods of promoting clearance of aggregates from the brain of the subject and of slowing progression of tangle-related behavioral phenotype in a subject.

Claims4

Dependent claims

An isolated immunogenic tau peptide consisting of the amino acid sequence of SEQ ID NO:2.

Dependencies are inferred from the claim text.

Facts

Application: 11/693,375Filed 29 Mar 2007 · us provisional application
Priority: 29 Mar 2006
Published: US 2008/0050383 A128 Feb 2008
Granted: 6 Sep 2011
Term ends: Not estimatedThe source records don’t support an estimate.

Classification11 codes

C07K 16/18
Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies: against material from animals or humans
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 39/3955
Against materials from animals: against proteinaceous materials, e.g. enzymes, hormones, lymphokines
A61P 25/28
Drugs for disorders of the nervous system: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents,…

Family

Application60/787,051Us provisional application · filed 29 Mar 2006
US 2008/0050383 A1Pre-grant publication · published 28 Feb 2008
US 8,012,936 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results